These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29523784)

  • 1. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
    Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
    Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.
    Nagai K; Ishii H; Miyoshi N; Hoshino H; Saito T; Sato T; Tomimaru Y; Kobayashi S; Nagano H; Sekimoto M; Doki Y; Mori M
    Biochem Biophys Res Commun; 2010 Apr; 395(2):258-63. PubMed ID: 20381452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
    Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
    Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG
    Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Transactivation and Transrepression in MYC-Driven Cancers.
    Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
    [No Abstract]   [Full Text] [Related]  

  • 9. Hold the MYCrophone: MYC Invades Enhancers to Control Cancer-Type Gene Programs.
    MacPherson-Hawthorne K; Sears RC
    Cancer Res; 2024 Jul; 84(14):2227-2228. PubMed ID: 38695859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.
    Cieśla M; Ngoc PCT; Cordero E; Martinez ÁS; Morsing M; Muthukumar S; Beneventi G; Madej M; Munita R; Jönsson T; Lövgren K; Ebbesson A; Nodin B; Hedenfalk I; Jirström K; Vallon-Christersson J; Honeth G; Staaf J; Incarnato D; Pietras K; Bosch A; Bellodi C
    Mol Cell; 2021 Apr; 81(7):1453-1468.e12. PubMed ID: 33662273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging roles of Myc in stem cell biology and novel tumor therapies.
    Yoshida GJ
    J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
    Aravalli RN; Talbot NC; Steer CJ
    World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules.
    Zviran A; Mor N; Rais Y; Gingold H; Peles S; Chomsky E; Viukov S; Buenrostro JD; Scognamiglio R; Weinberger L; Manor YS; Krupalnik V; Zerbib M; Hezroni H; Jaitin DA; Larastiaso D; Gilad S; Benjamin S; Gafni O; Mousa A; Ayyash M; Sheban D; Bayerl J; Aguilera-Castrejon A; Massarwa R; Maza I; Hanna S; Stelzer Y; Ulitsky I; Greenleaf WJ; Tanay A; Trumpp A; Amit I; Pilpel Y; Novershtern N; Hanna JH
    Cell Stem Cell; 2019 Feb; 24(2):328-341.e9. PubMed ID: 30554962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming.
    Marzi I; Cipolleschi MG; D'Amico M; Stivarou T; Rovida E; Vinci MC; Pandolfi S; Dello Sbarba P; Stecca B; Olivotto M
    Cell Cycle; 2013 Jan; 12(2):353-64. PubMed ID: 23287475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.
    Mishra P; Tang W; Putluri V; Dorsey TH; Jin F; Wang F; Zhu D; Amable L; Deng T; Zhang S; Killian JK; Wang Y; Minas TZ; Yfantis HG; Lee DH; Sreekumar A; Bustin M; Liu W; Putluri N; Ambs S
    J Clin Invest; 2018 Jan; 128(1):323-340. PubMed ID: 29202474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
    Shao P; Liu Q; Maina PK; Cui J; Bair TB; Li T; Umesalma S; Zhang W; Qi HH
    Nucleic Acids Res; 2017 Feb; 45(4):1687-1702. PubMed ID: 27899639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
    Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
    D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
    Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis.
    Feng D; Yan K; Zhou Y; Liang H; Liang J; Zhao W; Dong Z; Ling B
    Oncotarget; 2016 Oct; 7(40):64575-64588. PubMed ID: 27602489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.
    Zhuang Q; Li W; Benda C; Huang Z; Ahmed T; Liu P; Guo X; Ibañez DP; Luo Z; Zhang M; Abdul MM; Yang Z; Yang J; Huang Y; Zhang H; Huang D; Zhou J; Zhong X; Zhu X; Fu X; Fan W; Liu Y; Xu Y; Ward C; Khan MJ; Kanwal S; Mirza B; Tortorella MD; Tse HF; Chen J; Qin B; Bao X; Gao S; Hutchins AP; Esteban MA
    Nat Cell Biol; 2018 Apr; 20(4):400-412. PubMed ID: 29531310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.